Skip to main content
In 581 PsA pts (EuroSpA), MRI showed axial SpA features in 31%: BME (69%), erosions (68%), fat lesions (58%). MRI-axPsA

Antoni Chan MD (Prof) synovialjoints

1 year 1 month ago
In 581 PsA pts (EuroSpA), MRI showed axial SpA features in 31%: BME (69%), erosions (68%), fat lesions (58%). MRI-axPsA pts: younger (41y vs 46y), male (70%), HLA-B27+ (55%), ↑CRP (13 vs 7 mg/L). Radiographs identified sacroiliitis in 29%. MRI adds key detection. POS0297 https://t.co/nAw0BDAH22
Using high-resolution peripheral quantitative computed tomography (HR-pQCT), patients with psoriatic arthritis (PsA) &am

Antoni Chan MD (Prof) synovialjoints

1 year 1 month ago
Using high-resolution peripheral quantitative computed tomography (HR-pQCT), patients with psoriatic arthritis (PsA) & psoriasis (PsO) show reduced cortical volumetric bone mineral density (vBMD) & thinner cortex vs controls. Bone mechanics impaired: reduced stiffness & failure https://t.co/ghH2cwOYJc
#Shingrix #vaccination is Impt in #SLE
HZ vaccination works in SLE, safe – 1yr still good humeral & cellular immun

Janet Pope Janetbirdope

1 year 1 month ago
#Shingrix #vaccination is Impt in #SLE HZ vaccination works in SLE, safe – 1yr still good humeral & cellular immunity -attenuation over 1 yr re #immune #responses No major flares #shingles is ⬆️ in #lupus 👇 abnormal immune response #pred, #MMF #IS POS1005 #EULAR2025 @RheumNow https://t.co/o8lDXgOhE1
How does #HCQ work in #SLE

Stabilizes lysomal membranes?

#Lupus pts on HCQ monoRx & low #SLEDAI were followed

Si

Janet Pope Janetbirdope

1 year 1 month ago
How does #HCQ work in #SLE Stabilizes lysomal membranes? #Lupus pts on HCQ monoRx & low #SLEDAI were followed Single cell seq HCQ cytokine sigs May vary over time IFN & OXPosph pathways #Hydroxychloroquine in #LN - #IFN I&II #EULAR2025 @RheumNow POS0983 https://t.co/0gMQh9MNlg
#TDM for #HCQ warns of #toxic #levels in #CRF

v low GFR <30, <60, <90, >90
 
400mg/d all in low GFR toxic

Janet Pope Janetbirdope

1 year 1 month ago
#TDM for #HCQ warns of #toxic #levels in #CRF v low GFR <30, <60, <90, >90   400mg/d all in low GFR toxic   200mg/d 25% in low GFR toxic   6mg/kg/d – low GFR is too ⬆️ adjust HCQ dose for pts with CRF POS0987 #EULAR2025 @RheumNow @eular_org https://t.co/vg2b87LuiE
1/3 of #ERA pts poor
Outcomes despite controlled disease!
2 #RCT with T2T in early #RA
#CARERA
👇
persistent impact

Janet Pope Janetbirdope

1 year 1 month ago
1/3 of #ERA pts poor Outcomes despite controlled disease! 2 #RCT with T2T in early #RA #CARERA 👇 persistent impact ⬆️TJC, comorbidities ⬇️SJC, CRP, global, HAQ,  F>M ⬆️disease durat’n ▶️ ⬆️ b/tsDMARDs despite =diseaese vs others ?overRx OP0330 #EULAR2025 @RheumNow @eular_org
At EULAR 2025, there have been new developments in imaging in PsA.
Who/When to Treat Clinically Suspect Arthralgia

Dr. Jack Cush discusses risk stratification in Clinically suspect arthr

Dr. John Cush RheumNow

1 year 1 month ago
Who/When to Treat Clinically Suspect Arthralgia Dr. Jack Cush discusses risk stratification in Clinically suspect arthralgia; referencing EULAR2025 abstracts OP0004 (ALTO study) and OP0325 (long term Followup of ARRIA) https://t.co/FCO80mdHLg https://t.co/sX9u8mUoak
Procalcitonin can be used in the monitoring of infection, but is also high in Stills disease. 89 AOSD pts showed pts w h

Dr. John Cush RheumNow

1 year 1 month ago
Procalcitonin can be used in the monitoring of infection, but is also high in Stills disease. 89 AOSD pts showed pts w high PCT had more pleuritis, MAS,^LFTs, & correlated w/ Dz activity, CRP, LDH, hi ferritin & normalized w bDMARD Rx. #EULAR2025 abstr #POS1118 https://t.co/NpRA9optd3
"H Syndrome" review of 23 French pts. Autoinflammatory dz due to variants of SLC29A3 gene. Multisystem histiocytic lymph

Dr. John Cush RheumNow

1 year 1 month ago
"H Syndrome" review of 23 French pts. Autoinflammatory dz due to variants of SLC29A3 gene. Multisystem histiocytic lymphoproliferative disorder of young adults- skin 2/3, sensorineural hearing loss, fever w/ endo & autoimmune dz. Best responses w IL6 inhib. #EULAR2025 Abst https://t.co/F7NGI4TkJS
KORAIL cohort: new RA-ILD progression model (inc. DLCO, ILD pattern/extent, anti-CCP, ± KL-6) stratified risk with high

Mrinalini Dey DrMiniDey

1 year 1 month ago
KORAIL cohort: new RA-ILD progression model (inc. DLCO, ILD pattern/extent, anti-CCP, ± KL-6) stratified risk with high sensitivity & specificity. Adding KL-6 boosted AUC to 0.75. A step toward personalised care in RA-ILD. @RheumNow #EULAR2025 #OP0328 https://t.co/AHqNFw40gk
In real-world PsA, IL-23 inhibitors (guselkumab/risankizumab) showed clinical response in axial/mixed PsA. Best response

Antoni Chan MD (Prof) synovialjoints

1 year 1 month ago
In real-world PsA, IL-23 inhibitors (guselkumab/risankizumab) showed clinical response in axial/mixed PsA. Best response seen in pts meeting ASAS axial SpA criteria (RR 7.64) & baseline ASDAS-CRP >2.1. Supports role of patient stratification in axial PsA. Abstract#POS0113 https://t.co/qowZZmJOpM
#EULAR2025 Abstr#OP0281 Not just shredding the weight but now also the pain! Another potential benefit of GLP-1 agonists

Md Yuzaiful Md Yusof Yuz6Yusof

1 year 1 month ago
#EULAR2025 Abstr#OP0281 Not just shredding the weight but now also the pain! Another potential benefit of GLP-1 agonists - reducing symptoms of patients with Fibromyalgia. Propensity matched analysis using TrinetX database showed reduction on opiates, fatigue and pain @RheumNow https://t.co/oh6ecJmM5e
EULAR Daily Recap: Day 3
×